Si-Bone Form 4 Filings

SI-BONE, Inc. (SIBN) reported that Chief Executive Officer and director Laura Francis, through The David & Laura Joint Rev Tr., sold 25,972 shares of common stock on 2026-08-24 at a weighted-average price of $20.1215 per share, in transactions ranging from $20.00 to $20.24, pursuant to a Rule 10b5-1 trading plan dated May 21, 2026. Following this sale, the trust holds 291,491 shares indirectly, and Francis also has 493,900 shares held directly, including 355,697 shares issuable upon settlement of restricted stock units, each RSU representing a right to receive one share of common stock.

SI-BONE, Inc. (SIBN) reported that Anshul Maheshwari, its Chief Operating & Financial Officer, sold 11,636 shares of common stock on 2026-08-24 at a weighted-average price of $20.1075 per share under a Rule 10b5-1 trading plan dated December 17, 2025. After this sale, Maheshwari directly holds 223,284 shares, which include 167,604 shares issuable upon settlement of restricted stock units.

SI-BONE, Inc. (SIBN) reported that a trust associated with Chief Executive Officer and director Laura Francis sold shares of Common Stock under a Rule 10b5-1 trading plan dated May 21, 2026. On August 20, 2026, the trust sold 51,884 shares at a weighted-average price of $19.46 per share, in multiple transactions ranging from $19.10 to $19.73. On August 21, 2026, it sold an additional 3,923 shares at a weighted-average price of $20.02, in trades ranging from $20.00 to $20.05. Following these transactions, Laura Francis directly holds 493,900 shares, including 355,697 shares issuable upon settlement of restricted stock units.

SI-BONE, Inc. (SIBN) insider Anshul Maheshwari, Chief Op & Financial Officer, reported open-market sales of company common stock under a Rule 10b5-1 trading plan dated December 17, 2025. He sold 5,747 shares on August 19, 2026 at a weighted-average price of $19.55 and 11,228 shares on August 21, 2026 at a weighted-average price of $20.02, for total reported sales of 16,975 shares. Following these transactions, his direct holdings include 167,604 shares issuable upon settlement of restricted stock units.

SI-BONE, Inc. (SIBN) disclosed that Chief Executive Officer Laura Francis reported multiple same‑day open‑market sales totaling 14,956 shares of common stock on 2026-08-17 at weighted average prices around $18.63–$18.68 per share. Footnotes state these were "sell to cover" transactions executed to satisfy tax withholding obligations upon the vesting of restricted stock units and are not discretionary trades. After these trades, 373,270 shares are held indirectly by The David & Laura Joint Rev Tr., and an additional 355,697 shares are issuable upon settlement of restricted stock units granted to the reporting person.

SI-BONE, Inc. (SIBN) officer Michael A. Pisetsky, SVP, Ops & Adm/Chief Legal Officer, reported selling a total of 3,725 shares of common stock on August 17, 2026, in open-market transactions. According to the disclosure, these sales were required solely to cover tax withholding obligations from vesting restricted stock units under a “sell to cover” arrangement and did not represent discretionary trades. Following these transactions, Pisetsky’s reported holdings include 130,281 shares issuable upon settlement of restricted stock units, each unit representing a contingent right to one share of SI-BONE common stock.

SI-BONE, Inc. (SIBN) reported that its Chief Financial Officer, Anshul Maheshwari, sold a total of 4,665 shares of common stock on 2026-08-17 in two open-market transactions. Footnotes state these were “sell to cover” sales to satisfy tax withholding on vesting restricted stock units, described as non-discretionary. Following these transactions, Maheshwari’s holdings include 167,604 shares issuable upon settlement of restricted stock units.

SI-BONE director Jeffrey W. Dunn exercised stock options for 20,000 shares of common stock at $4.68 per share and on the same date sold 20,000 shares at a weighted-average price of $18.4607 pursuant to a Rule 10b5-1 plan dated May 7, 2025. Following these trades he holds 106,260 shares directly, including 10,957 underlying restricted stock units, plus 81,073 shares held indirectly through a living trust.

SI-BONE, Inc. executive Michael A. Pisetsky, SVP Operations & Administration and Chief Legal Officer, reported open-market sales of company common stock primarily to cover taxes on vested restricted stock units. On July 2, 2026, he sold 3,134 shares in three trades at prices around $16.70 per share under a “sell to cover” arrangement, which the company notes was not a discretionary trade. His equity position continues to include 137,587 shares issuable upon settlement of restricted stock units.

SI-BONE, Inc. Chief Financial Officer Anshul Maheshwari reported an open-market sale of 3,317 shares of common stock on July 2, 2026. The transactions were executed at weighted average prices of $16.7348 for 1,560 shares and $16.8017 for 1,757 shares.

According to the disclosure, these sales were required to cover tax withholding obligations tied to the vesting of restricted stock units, using a non-discretionary “sell to cover” arrangement. After these sales, Maheshwari directly holds 256,560 shares, including 177,141 shares issuable upon settlement of restricted stock units, so the reported sales represent only a small portion of his overall equity position.

HILLEMAN JERYL L reported acquisition or exercise transactions in this Form 4 filing.

SI-BONE, Inc. director Jeryl L. Hilleman received an equity grant in the form of 10,957 restricted stock units, each representing a contingent right to one share of common stock. The units were granted at $0.00 per share as director compensation, not an open-market purchase.

These restricted stock units will vest 100% on the earlier of the company’s next annual general meeting of stockholders or one year from the vesting commencement date, assuming continued board service. Following this award, Hilleman’s reported direct holdings total 43,772 shares of common stock, including the unvested units.

SI-BONE, Inc. director Jeffrey W. Dunn reported routine equity compensation and related tax sales. He received a grant of 10,957 shares of common stock as restricted stock units, which each represent a contingent right to one share and will vest in full at the earlier of the next annual stockholder meeting or one year from the vesting commencement date, subject to continued board service.

To cover tax withholding from RSU vesting, 3,575 shares of common stock were sold in open-market transactions at a weighted average price of $15.2462 per share in a non-discretionary “sell to cover” transaction. After these transactions, Dunn holds 16,057 shares directly and 81,073 shares indirectly through The Jeffrey W. Dunn Living Trust.

Nishimura Mika reported acquisition or exercise transactions in this Form 4 filing.

SI-BONE, Inc. director Mika Nishimura received a grant of 10,957 shares of common stock in the form of restricted stock units at no cash cost. Each unit represents a right to one share and will vest 100% at the next annual stockholder meeting or one year from the vesting start date, if she remains on the Board. Following this award, she directly holds 43,673 shares, including these unvested units.

West Thomas A. reported acquisition or exercise transactions in this Form 4 filing.

SI-BONE, Inc. director Thomas A. West reported receiving a grant of 10,957 shares of common stock in the form of restricted stock units at no cash cost. Following this award, he directly holds 37,947 shares, including 20,115 shares issuable upon settlement of previously granted restricted stock units.

The new restricted stock units will vest 100% on the earlier of the company’s next annual general meeting of stockholders or one year from the vesting commencement date, provided he continues to serve on the Board of Directors through that date.

SI-BONE, Inc. director John Gordon Freund reported a compensation-related equity grant rather than an open-market trade. He received 10,957 shares of Common Stock in the form of restricted stock units at $0.00 per share, classified as a grant or award acquisition. These restricted stock units will vest 100% on the earlier of the next annual general meeting of stockholders or one year from the vesting commencement date, subject to his continued board service. Following this award, he directly holds 54,258 shares, which include 10,957 shares issuable upon settlement of restricted stock units, and is also associated with 91,767 shares held indirectly through John Freund Family Partnership IV, L.P., for which he may be deemed to have voting and investment power but disclaims beneficial ownership except to the extent of his pecuniary interest.

Davis Timothy E JR reported acquisition or exercise transactions in this Form 4 filing.

SI-BONE, Inc. director Timothy E. Davis Jr. reported a grant of 10,957 restricted stock units (RSUs), each representing a contingent right to receive one share of common stock. These RSUs vest 100% at the earlier of the next annual general meeting or one year from the vesting commencement date, contingent on continued board service. Following this award, he is shown as directly holding 76,679 shares, including the RSUs.

SI-BONE, Inc. director Timothy E. Davis Jr. reported an option exercise and related share sales. On May 28, 2026, he exercised options for 12,064 shares of common stock at $4.32 per share, then sold 3,780 shares at a weighted average price of $14.4706. On May 29, 2026, he sold an additional 3,500 shares at a weighted average price of $14.1394. Following these transactions, he held 65,722 shares directly. A footnote states that this holding includes 8,675 shares issuable on settlement of restricted stock units.

SI-BONE, Inc.’s Chief Executive Officer Laura Francis reported open-market sales of 14,957 shares of common stock on May 18, 2026, at weighted average prices around the mid-$14 range. According to the disclosure, these shares were sold solely to cover tax withholding obligations tied to vesting restricted stock units and were not discretionary trades.

Following the sales, Francis directly holds 503,444 shares of SI-BONE common stock. She also has indirect ownership of additional shares held by a family trust, providing substantial ongoing equity exposure despite the tax-related share sales.

SI-BONE, Inc. senior vice president and chief legal officer Michael A. Pisetsky reported selling 3,726 shares of common stock on May 18, 2026 in open-market transactions at weighted average prices around $14.63 per share.

According to the disclosure, these sales were required to cover tax withholding obligations tied to the vesting of restricted stock units and were executed as automatic “sell to cover” transactions, not discretionary trades. He also holds 1,395 shares acquired under the 2018 Employee Stock Purchase Plan on May 15, 2026, and 143,729 shares issuable upon settlement of restricted stock units.

SI-BONE, Inc. Chief Financial Officer Anshul Maheshwari reported two open-market sales of common stock that were executed solely to cover tax withholding from vested restricted stock units. The transactions totaled 4,666 shares, sold at weighted average prices of $14.6545 and $14.7132 per share.

A footnote explains these were mandatory "sell to cover" trades and not discretionary sales. Another footnote notes 1,395 shares acquired under the 2018 Employee Stock Purchase Plan and 183,921 shares issuable upon settlement of outstanding restricted stock units, indicating a substantial remaining equity position tied to future vesting.

SI-BONE, Inc. director Jeffrey W. Dunn reported a small, non-discretionary share sale tied to taxes. On May 4, 2026, a total of 337 shares of Common Stock were sold at a weighted average price of $13.1508 solely to cover tax withholding obligations from the vesting of restricted stock units under a “sell to cover” arrangement. Following this transaction, Dunn holds 9,157 shares directly, which include 8,675 shares issuable upon settlement of restricted stock units, and 80,591 shares indirectly through The Jeffrey W. Dunn Living Trust.

SI-BONE, Inc. director Greg K. Hinckley exercised stock options to acquire 3,085 shares of common stock at an exercise price of $5.94 per share. Following the transaction, he directly owns 105,135 shares of common stock.

This direct holding figure includes 8,675 shares issuable upon settlement of restricted stock units, each representing a right to receive one share of common stock. A portion of the shares is held with his spouse as community property with right of survivorship. The option exercised was part of a grant that vested in equal monthly installments over three years beginning on October 17, 2018.

SI-BONE, Inc. Chief Financial Officer Anshul Maheshwari reported selling 3,318 shares of common stock in two open-market transactions on April 2, 2026, at weighted average prices of $12.9228 and $12.8137 per share.

According to the footnotes, these sales were required to cover tax withholding obligations arising from the vesting of restricted stock units and were executed as "sell to cover" transactions, rather than discretionary trades. After these sales, Maheshwari directly owns 263,148 shares of SI-BONE common stock, including 193,458 shares issuable upon settlement of restricted stock units.

SI-BONE, Inc. senior vice president and chief legal officer Michael A. Pisetsky reported selling a total of 3,134 shares of common stock in open-market transactions on April 1–2, described as sales required to cover tax withholding on vesting restricted stock units under a “sell to cover” arrangement, rather than discretionary trades.

Sale prices ranged from about $12.55 to $13.09, with weighted averages around the reported prices. After these transactions, he holds 282,840 shares directly, which the disclosure states includes 151,034 shares issuable upon settlement of restricted stock units.

SI-BONE, Inc. director Mika Nishimura reported an open-market sale of 4,100 shares of Common Stock. The shares were sold on March 12, 2026 at a weighted average price of $13.8293 per share, with individual trade prices ranging from $13.82 to $13.86.

After this transaction, Nishimura directly holds 32,716 shares of SI-BONE common stock. This figure includes 8,675 shares issuable upon settlement of restricted stock units, each of which represents a contingent right to receive one share of common stock. No option exercises or derivative transactions were reported.

SI-BONE, Inc. reporting person Anthony J. Recupero reported multiple open-market sales of common stock on February 17, 2026 totaling 21,049 shares at weighted-average prices around the mid‑$15 range. The filing states these shares were sold under a “sell to cover” arrangement to satisfy tax withholding obligations from vesting restricted stock units, and therefore were not discretionary trades. After these sales, Recupero reported ownership of 243,418 shares of common stock, which the footnotes state includes 83,423 shares issuable upon settlement of restricted stock units.

SI-BONE, Inc. reported that executive Michael A. Pisetsky, SVP of Operations & Administration and Chief Legal Officer, received several stock awards and sold shares primarily to cover taxes. On February 16, 2026, he acquired 58,720 shares of common stock and two additional grants of 9,787 shares each as restricted stock unit awards, at a stated price of $0.00 per share, reflecting equity compensation that will vest over multi-year periods based on service and, for one grant, relative total shareholder return performance.

On February 17, 2026, he executed open-market sales totaling 20,756 shares of common stock at weighted average prices around $15.31–$15.41 per share. Footnotes state these sales were required to satisfy tax withholding obligations from RSU vesting through “sell to cover” transactions and were not discretionary trades. After these transactions, he continued to hold a substantial share position, including 157,176 shares issuable upon settlement of restricted stock units.

SI-BONE, Inc. director and Chief Executive Officer Laura Francis reported a mix of stock awards and sales. On February 16, 2026, she acquired a total of 229,481 shares of common stock through grants and restricted stock unit awards at a stated price of $0.00 per share, which will vest over three to four years based on time and total shareholder return performance conditions. On February 17, 2026, she sold 93,475 shares of common stock in a series of open-market transactions at weighted average prices around $15.30 per share to cover tax withholding obligations from vesting restricted stock units, as disclosed in a footnote. Following these sales, she directly owned 544,369 shares, including 414,439 shares issuable upon settlement of restricted stock units, and an additional 351,319 shares were held indirectly by The David & Laura Joint Rev Tr.

SI-BONE, Inc.’s Chief Financial Officer Anshul Maheshwari reported a mix of equity awards and related share sales. On February 16, 2026, he acquired a total of 107,992 shares of common stock through grants of restricted stock units, which vest over multi‑year periods based on time and total shareholder return performance.

On February 17, 2026, he sold 21,528 shares of common stock in multiple open‑market transactions at prices between $15.18 and $15.62. Footnotes state these sales were solely to cover tax withholding obligations from RSU vesting under a sell‑to‑cover arrangement and were not discretionary trades.

SI-BONE, Inc. director Jeffrey W. Dunn reported a small sale of company stock tied to tax obligations. On February 2, 2026, he sold 337 shares of common stock at a weighted average price of $16.4157 per share.

The footnotes explain this was a mandatory "sell to cover" transaction to satisfy tax withholding from vesting restricted stock units, and not a discretionary trade. After the sale, Dunn beneficially owned 9,970 shares directly, including 9,491 shares issuable upon settlement of restricted stock units, and 80,115 shares indirectly held by The Jeffrey W. Dunn Living Trust Dated May 17, 2012.

SI-BONE director Jeffrey W. Dunn, through The Jeffrey W. Dunn Living Trust Dated May 17, 2012, reported selling 20,000 shares of SI-BONE common stock on January 8, 2026. The sale was executed under a pre-arranged Rule 10b5-1 trading plan dated May 7, 2025 at a weighted-average price of $21.2753 per share, with individual trade prices ranging from $20.84 to $21.84.

Following the sale, the trust held 80,115 shares indirectly, while Dunn also had 10,307 shares directly, including shares issuable upon settlement of restricted stock units. Each restricted stock unit represents a contingent right to receive one share of SI-BONE common stock.

SI-BONE, Inc. executive reports tax-related share sale

SI-BONE, Inc. Senior Vice President, Operations & Administration and Chief Legal Officer Michael A. Pisetsky reported selling small amounts of the company’s common stock on January 2, 2026. The sales, executed in three trades at prices of $19.75, $19.6811, and $19.5788 per share, were made to cover tax withholding obligations tied to the vesting of restricted stock units. According to the disclosure, this was a mandated “sell to cover” transaction and not a discretionary trade.

After these sales, Pisetsky beneficially owned 228,436 shares of SI-BONE common stock directly. This amount includes 119,679 shares that are issuable upon settlement of restricted stock units, each unit representing the right to receive one share of common stock.

SI-BONE, Inc. director Jeffrey W. Dunn reported a series of transactions in the company’s common stock. On December 8, 2025, he exercised a stock option for 1,241 shares at an exercise price of $4.32 per share and acquired those shares.

That same day, he sold 1,241 shares of common stock and separately sold another 18,759 shares, both reported with a weighted-average sale price of $19.3297 per share, with individual sale prices ranging from $19.13 to $19.85. The sales were made under a Rule 10b5-1 trading plan dated May 7, 2025. After these transactions, he beneficially owned 10,307 shares directly, including shares issuable on settlement of restricted stock units, and 110,115 shares indirectly through The Jeffrey W. Dunn Living Trust dated May 17, 2012.

SI-BONE, Inc. (SIBN) reported an insider transaction by its SVP, Ops & Adm/Chief Legal Officer. On 11/24/2025, the officer sold 400 shares of common stock at $20 per share, reported with transaction code "S" for a sale. The filing notes that this trade was made under a Rule 10b5-1 trading plan dated June 13, 2025, which is a pre-arranged plan for selling shares.

After this transaction, the reporting person beneficially owned 251,496 shares of SI-BONE common stock. This total includes 125,823 shares issuable upon settlement of restricted stock units, where each unit represents the right to receive one share of common stock.

SI-BONE, Inc. (SIBN) filed a Form 4 reporting stock sales by its Chief Financial Officer, Anshul Maheshwari. The CFO sold 1,200 shares of common stock on 11/21/2025 at a weighted-average price of about $20.0133 per share and an additional 100 shares on 11/25/2025 at $20.00 per share. These sales were made under a pre-arranged Rule 10b5-1 trading plan dated December 13, 2024, which is designed to allow insiders to sell stock according to a set schedule.

Following these transactions, Maheshwari beneficially owns 203,773 shares of SI-BONE common stock. This total includes 143,116 shares issuable upon settlement of restricted stock units, each representing a right to receive one share of common stock.

SI-BONE, Inc. (SIBN) reported an insider transaction by its President, Commercial Ops, Anthony J. Recupero. On 11/17/2025, he sold 1,707 and 2,126 shares of common stock in two transactions at weighted average prices of $17.4232 and $17.4462, respectively. These sales were made to cover tax withholding obligations arising from the vesting of restricted stock units and are described as non-discretionary “sell to cover” trades.

Following these transactions, the reporting person beneficially owned 268,144 shares of SI-BONE common stock, including 133,316 shares issuable upon settlement of restricted stock units, with each unit representing a contingent right to receive one share.

SI-BONE, Inc. (SIBN) reported an insider transaction by its Senior Vice President, Operations & Administration and Chief Legal Officer on 11/17/2025. The executive sold 1,478 and 1,850 shares of common stock in two separate trades, coded as sales.

According to the disclosure, these sales were made solely to cover tax withholding obligations arising from the vesting of restricted stock units under a "sell to cover" arrangement and are described as non-discretionary trades. After the transactions, the reporting person beneficially owned 251,896 shares of common stock, including 125,823 shares issuable upon settlement of restricted stock units, each unit representing a right to receive one share.

SI-BONE, Inc. insider trading report: The Chief Financial Officer of SI-BONE, Inc. (SIBN) reported two sales of common stock on 11/17/2025 totaling 3,460 shares. One sale covered 1,275 shares at a weighted average price of $17.4098, and another covered 2,185 shares at a weighted average price of $17.4369. According to the disclosure, these transactions were "sell to cover" sales required to satisfy tax withholding obligations related to vesting restricted stock units and were not discretionary trades. After these transactions, the reporting person beneficially owned 205,073 shares of common stock, including 143,116 shares issuable upon settlement of restricted stock units.

SI-BONE, Inc. (SIBN) reported insider transactions by Chief Executive Officer and Director Laura A. Francis. On 11/17/2025, she sold several small blocks of common stock, including 2,028 shares at a weighted average price of $17.4401, 2,231 shares at $17.4449, 3,197 shares at $17.4341, and 3,885 shares at $17.3996.

The filing explains that these sales were required to cover tax withholding obligations tied to the vesting of restricted stock units and were executed as "sell to cover" transactions rather than discretionary trades. On 11/18/2025, 5,411 additional shares were sold at a weighted average price of $17.6978 under a Rule 10b5-1 trading plan dated December 13, 2024.

After these transactions, Francis beneficially owned 408,363 shares directly, including 373,980 shares issuable upon settlement of restricted stock units, and 351,319 shares indirectly through a trust.

SI-BONE (SIBN) reported an insider transaction by CEO and Director Laura A. Francis. She sold 5,411 shares of common stock on 11/11/2025 at a weighted‑average price of $17.0591, effected under a Rule 10b5-1 trading plan dated December 13, 2024.

After the sale, 356,730 shares were held indirectly by a trust, and 419,704 shares were held directly. The direct figure includes 396,297 shares issuable upon settlement of restricted stock units.

SI-BONE (SIBN) director Jeffrey W. Dunn reported option exercises and related sales on 11/11/2025. He exercised stock options at $4.32 for 23,148 shares and 56,852 shares, then sold the same amounts at $18.95 per share pursuant to a Rule 10b5-1 trading plan dated May 7, 2025.

Following these transactions, he directly held 10,307 shares. He also had indirect ownership of 118,874 shares held by The Jeffrey W. Dunn Living Trust. The direct total includes 10,307 shares issuable upon settlement of restricted stock units, each representing one share of common stock. The option awards referenced vest in equal monthly installments over four years, subject to continued service.

SI-BONE (SIBN) reported a Form 4 for CFO Anshul Maheshwari. On 11/11/2025, he sold 2,601 shares of common stock at a weighted-average price of $18.3333, executed under a Rule 10b5-1 trading plan dated December 13, 2024. Following the sale, he beneficially owns 208,533 shares, which include 150,203 shares issuable upon settlement of restricted stock units. Ownership is listed as direct.

SI‑BONE (SIBN) director reported a routine insider transaction. On 11/03/2025, the reporting person sold 293 shares of common stock at a weighted average price of $14.8038. The filing states this was a sell‑to‑cover to satisfy tax withholding from vesting RSUs, not a discretionary trade.

Following the transaction, the filer beneficially owns 10,831 shares directly and 118,350 shares indirectly via a trust. The direct holdings include 10,307 shares issuable upon settlement of restricted stock units, each representing one share.

SI-BONE, Inc. (SIBN) reported insider sales by Michael A. Pisetsky, SVP, Ops & Adm/Chief Legal Officer, on 10/02/2025. The Form 4 shows a total of 3,128 shares of common stock sold across multiple trades to satisfy tax withholding on vesting restricted stock units; these sales are described as a "sell to cover" and not discretionary. Reported weighted average prices per transaction are $14.255, $14.1053, and $14.2537, and the filing lists 256,556, 256,522, and 255,224 shares beneficially owned after each reported sale line. The filing also discloses 132,362 shares issuable on settlement of restricted stock units retained by the reporting person.

SI-BONE, Inc. Chief Financial Officer Anshul Maheshwari reported selling a total of 3,311 shares of common stock on October 2, 2025, in open-market transactions at weighted average prices of $14.2237 and $14.1711 per share.

The company states these shares were sold solely to cover tax withholding obligations arising from the vesting of restricted stock units under a "sell to cover" arrangement and did not represent a discretionary trade by the CFO. After these transactions, Maheshwari directly holds 211,134 shares of common stock, including 150,203 shares issuable upon settlement of restricted stock units.

SI-BONE, Inc. (SIBN) reported an insider transaction by its President, Commercial Ops, Anthony J. Recupero. On 10/02/2025, he sold 1,557 shares at a weighted average price of $14.2374 and 1,754 shares at a weighted average price of $14.27.

The filing states these were sell-to-cover sales to satisfy tax withholding upon RSU vesting and were not discretionary trades. Following the transactions, he beneficially owned 271,977 shares. This total includes 141,167 shares issuable upon settlement of restricted stock units, with each RSU representing one share.